RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia

Blood

Volumn 118, Issue 3, 2011, Pages 638-649

  Holland, Mark ^a   Castro, Fernanda V ^b   Alexander, Seema ^a   Smith, Duncan ^b   Liu, Jizhong ^a   Walker, Michael ^a   Bitton, Danny ^b   Mulryan, Kate ^b   Ashton, Garry ^b   Blaylock, Morgan ^b   Bagley, Steve ^b   Connolly, Yvonne ^b   Bridgeman, John ^a   Miller, Crispin ^b   Krishnan, Shekhar ^a   Dempsey, Clare ^a   Masurekar, Ashish ^a   Stern, Peter ^b   Whetton, Anthony ^a   Saha, Vaskar ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD70 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LEGUMAIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RAC2 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LEUKEMIA; BONE MARROW BIOPSY; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM LEUKEMIA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA RELAPSE; LYMPHOBLAST; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; UNINDEXED SEQUENCE;

EID: 79960666593     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307330     Document Type: Article

References (52)

1. Krishnan S, Wade R, Moorman AV, et al. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010;24(2):450-459.
2. Hagedorn N, Acquaviva C, Fronkova E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood. 2007;110(12):4022-4029. (Pubitemid 350248458)
3. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322(5906):1377- 1380. (Pubitemid 352775249)
4. Strefford JC, van Delft FW, Robinson HM, et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A. 2006;103(21):8167-8172. (Pubitemid 43801070)
5. Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003;63(11):2957-2964. (Pubitemid 36667169)
6. Murthy RV, Arbman G, Gao J, Roodman GD, Sun XF. Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 2005;11(6):2293-2299. (Pubitemid 40490189)
7. Wu W, Luo Y, Sun C, et al. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 2006;66(2):970-980. (Pubitemid 43165965)
8. Chen JM, Fortunato M, Stevens RA, Barrett AJ. Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem. 2001;382(5):777-783. (Pubitemid 32631714)
9. Patel N, Krishnan S, Offman MN, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest. 2009;119(7):1964-1973.
10. Akbar H, Cancelas J, Williams DA, Zheng J, Zheng Y. Rational design and applications of a Rac GTPase-specific small molecule inhibitor. Methods Enzymol. 2006;406:554-565. (Pubitemid 43207468)
11. Ramjeesingh M, Kidd JF, Huan LJ, Wang Y, Bear CE. Dimeric cystic fibrosis transmembrane conductance regulator exists in the plasma membrane. Biochem J. 2003;374(pt 3):793-797. (Pubitemid 37163927)
12. Yates JR, Cociorva D, Liao L, Zabrouskov V. Performance of a linear ion trap-Orbitrap hybrid for peptide analysis. Anal Chem. 2006;78(2):493-500. (Pubitemid 43100382)
13. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
14. Gilham DE, O'Neil A, Hughes C, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother. 2002;25(2):139-151. (Pubitemid 34260765)
15. Naresh KN, Lampert I, Hasserjian R, et al. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol. 2006;59(9):903-911. (Pubitemid 44422841)
16. Loak K, Li DN, Manoury B, et al. Novel cell-permeable acyloxymethylketone inhibitors of asparaginyl endopeptidase. Biol Chem. 2003; 384(8):1239-1246. (Pubitemid 37121195)
17. Halfon S, Patel S, Vega F, Zurawski S, Zurawski G. Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett. 1998;438(1-2):114-118. (Pubitemid 28517846)
18. Pierce A, Unwin RD, Evans CA, et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics. 2008;7(5):853-863. (Pubitemid 351737087)
19. Lund TC, Anderson LB, McCullar V, et al. iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types. J Proteome Res. 2007;6(2):644-653. (Pubitemid 46340168)
20. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952-958. (Pubitemid 44871421)
21. Leth-Larsen R, Lund R, Hansen HV, et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics. 2009;8(6):1436-1449.
22. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29. (Pubitemid 30257031)
23. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3(8):586-599.
24. Li Y, Guerrero A, Howard TH. The actin-binding protein, lymphocyte-specific protein 1, is expressed in human leukocytes and human myeloid and lymphoid cell lines. J Immunol. 1995;155(7):3563-3569.
25. Al Tanoury Z, Schaffner-Reckinger E, Halavatyi A, et al. Quantitative kinetic study of the actin-bundling protein L-plastin and of its impact on actin turn-over. PLoS ONE. 2010;5(2):e9210.
26. Laux T, Fukami K, Thelen M, Golub T, Frey D, Caroni P. GAP43, MARCKS, and CAP23 modulate PI(4,5)P(2) at plasmalemmal rafts, and regulate cell cortex actin dynamics through a common mechanism. J Cell Biol. 2000;149(7):1455-1472.
27. Langereis JD, Prinsen BH, de Sainvan der Velden MG, Coppens CJ, Koenderman L, Ulfman LH. A 2D-DIGE approach to identify proteins involved in inside-out control of integrins. J Proteome Res. 2009;8(8):3824-3833.
28. Carrasco YR, Fleire SJ, Cameron T, Dustin ML, Batista FD. LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation. Immunity. 2004;20(5):589-599. (Pubitemid 38638128)
29. Arana E, Vehlow A, Harwood NE, et al. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunologicalsynapse formation. Immunity. 2008;28(1):88-99.
30. Sun CX, Magalhaes MA, Glogauer M. Rac1 and Rac2 differentially regulate actin free barbed end formation downstream of the fMLP receptor. J Cell Biol. 2007;179(2):239-245. (Pubitemid 350004888)
31. Mengarelli A, Zarcone D, Caruso R, et al. Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2001;40(5-6):625-630. (Pubitemid 32303251)
32. Hara J, Matsuda Y, Fujisaki H, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol. 2000;72(1):69-73.
33. Nilsson A, de Milito A, Mowafi F, et al. Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. Exp Hematol. 2005;33(12):1500-1507. (Pubitemid 41781986)
34. Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol. 2004;173(6):3901-3908. (Pubitemid 39280753)
35. Gu Y, Filippi MD, Cancelas JA, et al. Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science. 2003;302(5644):445-449. (Pubitemid 37296270)
36. Sanz-Moreno V, Gadea G, Ahn J, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell. 2008;135(3):510-523.
37. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med. 2005;11(8):886-891. (Pubitemid 41161122)
38. Jansen M, Yang FC, Cancelas JA, Bailey JR, Williams DA. Rac2-deficient hematopoietic stem cells show defective interaction with the hematopoietic microenvironment and long-term engraftment failure. Stem Cells. 2005;23(3):335-346. (Pubitemid 40404452)
39. Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003;198(10):1539-1550. (Pubitemid 37467168)
40. McEarchern JA, Smith LM, McDonagh CF, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res. 2008;14(23):7763-7772.
41. Petty RD, Kerr KM, Murray GI, et al. Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer. J Clin Oncol. 2006;24(11):1729-1744. (Pubitemid 46622145)
42. Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R. Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. Br J Pharmacol. 2008;153(6):1153-1161. (Pubitemid 351415495)
43. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 2007;12(5):467-478. (Pubitemid 350046406)
44. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. (Pubitemid 46220637)
45. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827- 1833. (Pubitemid 351451489)
46. Perk K, Pearson JW, Torgersen JA, Chirigos MA. An animal model for meningeal leukemia. Int J Cancer. 1974;13(6):863-866.
47. Thomas LB, Chirigos MA, Humphreys SR, Goldin A. Development of meningeal leukemia (L1210) during treatment of subcutaneously inoculated mice with methotrexate. Cancer. 1964;17:352-360.
48. Kumagai M, Manabe A, Pui CH, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest. 1996;97(3):755-760. (Pubitemid 26057095)
49. Buonamici S, Trimarchi T, Ruocco MG, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 2009;459(7249):1000-1004.
50. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A. 2003;100(10):5813-5818. (Pubitemid 36576890)
51. Mielenz D, Vettermann C, Hampel M, et al. Lipid rafts associate with intracellular B cell receptors and exhibit a B cell stage-specific protein composition. J Immunol. 2005;174(6):3508-3517. (Pubitemid 40354059)
52. Saeki K, Miura Y, Aki D, Kurosaki T, Yoshimura A. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. EMBO J. 2003;22(12):3015-3026. (Pubitemid 36758622)